• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

描述转移性结直肠癌各疾病阶段的医疗护理。

Characterizing medical care by disease phase in metastatic colorectal cancer.

机构信息

Thomson Reuters, 4301 Connecticut Ave, Washington, DC 20008, USA.

出版信息

Am J Manag Care. 2011 May;17 Suppl 5 Developing:SP20-5.

PMID:21711074
Abstract

OBJECTIVE

To characterize patterns of medical care by disease phase in patients with newly diagnosed metastatic colorectal cancer (mCRC).

METHODS

Patients with mCRC newly diagnosed between 2004 and 2008 were selected from a large US national commercially insured claims database and were observed from initial mCRC diagnosis to death, disenrollment, or end of study period (July 31, 2009), whichever occurred first. The observation period was divided into 3 distinct phases of disease: diagnostic, treatment, and death. Within each phase, patterns of medical care were examined by the mutually exclusive service categories of inpatient, emergency department (ED), outpatient office and facility, outpatient pharmacy, chemotherapy, and biologic therapy, as measured by estimation of aggregate and category costs per patient per month.

RESULTS

A total of 6675 patients with newly diagnosed mCRC were analyzed. Mean age was 64.1 years; 55.5% were males. Mean costs per patient per month for diagnostic, treatment, and death phases were $16,895, $8891, and $27,554, respectively. Inpatient care was the primary driver of medical care for both the diagnostic (41.7% of costs) and death (71.4% of costs) phases. The largest category of medical care for the treatment phase was outpatient care (45.0% of costs). Chemotherapy and biologic therapy accounted for 15.6% and 17.6% of costs in the treatment phase, respectively.

CONCLUSION

Substantial differences in patterns of medical care were found between mCRC disease phases. Inpatient care was the key driver of medical care in the diagnostic and death phases compared with outpatient care in the treatment phase.

摘要

目的

描述新诊断转移性结直肠癌(mCRC)患者疾病各阶段的医疗护理模式。

方法

从美国一个大型商业保险索赔数据库中选择 2004 年至 2008 年间新诊断为 mCRC 的患者,并从初始 mCRC 诊断至死亡、退保或研究期末(2009 年 7 月 31 日)进行观察,以先发生者为准。观察期分为疾病的 3 个不同阶段:诊断、治疗和死亡。在每个阶段内,通过每月每位患者的总费用和类别费用来评估住院、急诊部(ED)、门诊办公室和医疗机构、门诊药房、化疗和生物治疗的相互排斥的服务类别来检查医疗护理模式。

结果

共分析了 6675 例新诊断的 mCRC 患者。平均年龄为 64.1 岁;55.5%为男性。诊断、治疗和死亡阶段每位患者每月的平均费用分别为 16895 美元、8891 美元和 27554 美元。住院治疗是诊断(占费用的 41.7%)和死亡(占费用的 71.4%)阶段医疗护理的主要驱动因素。治疗阶段医疗护理的最大类别是门诊护理(占费用的 45.0%)。化疗和生物治疗分别占治疗阶段费用的 15.6%和 17.6%。

结论

在 mCRC 疾病阶段之间发现了医疗护理模式的显著差异。与治疗阶段的门诊护理相比,住院治疗是诊断和死亡阶段医疗护理的关键驱动因素。

相似文献

1
Characterizing medical care by disease phase in metastatic colorectal cancer.描述转移性结直肠癌各疾病阶段的医疗护理。
Am J Manag Care. 2011 May;17 Suppl 5 Developing:SP20-5.
2
Characterizing medical care by disease phase in metastatic colorectal cancer.描述转移性结直肠癌各疾病阶段的医疗护理。
J Oncol Pract. 2011 May;7(3 Suppl):25s-30s. doi: 10.1200/JOP.2011.000304.
3
Healthcare costs associated with bevacizumab and cetuximab in second-line treatment of metastatic colorectal cancer.贝伐珠单抗和西妥昔单抗二线治疗转移性结直肠癌的相关医疗费用。
J Med Econ. 2011;14(5):542-52. doi: 10.3111/13696998.2011.596600. Epub 2011 Jul 6.
4
Corroboration of claims algorithm for second-line costs of metastatic colorectal cancer treatment with targeted agents.伴有靶向药物的转移性结直肠癌二线治疗的二线成本的主张验证算法。
J Med Econ. 2013 Aug;16(8):1071-81. doi: 10.3111/13696998.2013.813513. Epub 2013 Jul 5.
5
Estimating costs of care for patients with newly diagnosed metastatic colorectal cancer.估算新诊断转移性结直肠癌患者的护理费用。
Clin Colorectal Cancer. 2006 May;6(1):52-8. doi: 10.3816/CCC.2006.n.021.
6
The economic burden of lung cancer and the associated costs of treatment failure in the United States.美国肺癌的经济负担及治疗失败的相关成本。
Lung Cancer. 2005 Nov;50(2):143-54. doi: 10.1016/j.lungcan.2005.06.005. Epub 2005 Aug 19.
7
Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.患有和不患有肾炎的系统性红斑狼疮患者的经济结局:来自美国索赔数据库数据分析的结果。
Clin Ther. 2009 Nov;31(11):2653-64. doi: 10.1016/j.clinthera.2009.11.032.
8
Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.促红细胞生成素对慢性肾脏病患者医疗资源利用、费用及预后的影响
Ann Pharmacother. 2007 Nov;41(11):1761-9. doi: 10.1345/aph.1K194. Epub 2007 Sep 25.
9
Costs of hospital events in patients with metastatic colorectal cancer.转移性结直肠癌患者的医院事件成本。
J Med Econ. 2011;14(5):656-61. doi: 10.3111/13696998.2011.610394. Epub 2011 Aug 19.
10
Patterns of treatment, healthcare utilization and costs by lines of therapy in metastatic breast cancer in a large insured US population.在一个大型美国参保人群中,转移性乳腺癌的治疗模式、医疗保健利用和各治疗线的费用。
J Comp Eff Res. 2013 Mar;2(2):195-206. doi: 10.2217/cer.13.1.

引用本文的文献

1
Angiogenesis in primary colorectal cancer and matched metastatic tissues: Biological and clinical implications for anti-angiogenic therapies.原发性结直肠癌及配对转移组织中的血管生成:抗血管生成治疗的生物学和临床意义
Oncol Lett. 2020 May;19(5):3558-3566. doi: 10.3892/ol.2020.11450. Epub 2020 Mar 6.
2
The impact of travel time on colorectal cancer stage at diagnosis in a privately insured population.出行时间对参保人群结直肠癌确诊分期的影响。
BMC Health Serv Res. 2019 Mar 18;19(1):172. doi: 10.1186/s12913-019-4004-6.
3
Targeted therapy in advanced metastatic colorectal cancer: current concepts and perspectives.
晚期转移性结直肠癌的靶向治疗:当前概念与展望
World J Gastroenterol. 2014 May 28;20(20):6102-12. doi: 10.3748/wjg.v20.i20.6102.